Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences

Ana Cardeña-Gutiérrez* and Mónica López Barahona

1 Medical Oncology Department, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain, 2 Centro Estudios Biosanitarios, Madrid, Spain

Immune checkpoint inhibitors (ICIs) have dramatically transformed oncology by prolonging overall survival and yielding better patient tolerance compared to other chemotherapeutic agents. However, numerous questions remain unanswered about the toxicity profile of ICIs, its relationship with the treatment response, and causes underlying the excellent treatment response in some patients, while recalcitrance in others. Research groups have continued to seek biomarkers that may permit the identification of treatment responders and predict toxicity to facilitate cessation of immunotherapy before the development of severe toxicity. However, some studies have found associations between serious adverse events and longer survivorship. The research question entailed determining whether a biomarker is needed to predict severe immune-related adverse events prior to their development or whether providing early treatment for toxicity would inhibit the immune system from attaining a long-lasting anti-tumor effect. Therefore, this review conducted an in-depth analysis into the molecular basis of these observations.

Keywords: immune checkpoint proteins, immune-related adverse event (irAE), biomarker, autoimmunity, severe toxicity

INTRODUCTION

Immune checkpoint inhibitors (ICIs) have sparked a massive revolution in oncology. Immune checkpoints are a group of membrane receptors present on cytotoxic T lymphocytes whose function is to prevent an indefinite immune response that could severely damage healthy host tissue. Programmed cell death protein 1 (PD1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) are the most studied immune checkpoints. ICIs are monoclonal antibodies that target PD-1/programmed death ligand 1 (PD-L1) or CTLA-4, reactivating the anti-tumor immune response that is inhibited by the overexpression of these proteins by tumor cells (1). However, not all patients respond to immune checkpoint blockade. Response rates range from 13 to 40%, depending on monotherapy or combination treatment and the primary tumor (1). Hence, it imperative to discover biomarkers that can aid in predicting the treatment response to avoid the administration of ineffective drugs, which are also exorbitantly expensive. Despite tremendous efforts in this field, PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability are the only predictors available for use in routine clinical practice (2), although their specificity is not ideal.
Immune-related adverse events: molecular basis

Immune checkpoints play a fundamental role in maintaining immunologic homeostasis (6). Therefore, the blockade of these checkpoints may increase the anti-tumor activity of the immune system, which is accompanied by the risk of the loss of self-tolerance, leading to the occurrence of irAEs, causing damage to normal cells and tissues. CTLA4 modulates the immune response in the early stages, while PD-1 acts later in the immunologic cycle (1, 12). CTLA-4 blockade induces expansion of the inducible T-cell costimulatory Th1-like CD4 effect or as well as exhausted-like TCD8+ cells, while PD-1 blockade primarily induces expansion of exhausted-like tumor infiltrating TCD8+ cells (18).

The deficiency of CTLA-4 leads to severe autoimmune diseases (colitis and myocarditis) characterized by T-cell infiltration in murine models. This phenomenon also occurs with the loss of PD-1, but is less straightforward with genetic strain differences, and may be accompanied by the development of the late-onset autoimmune diseases (such as lupus-like disease) (19).

The self-tolerance of the immune system, in which regulatory T (Treg) cells play a fundamental role, can be lost in several ways. Tregs are a subgroup of CD4 + T lymphocytes that maintain immune tolerance. Usually, a higher count of Tregs in peripheral blood is related with poor prognosis for several cancers (20). Nuclear factor kappa B (NF-kB) activation is essential for Treg-induced homeostasis, and Treg and effector T-cell expansion (21). Constitutive activation of NF-kB-induced kinase (NIK) on Tregs induces alteration of its functions and genetic signature (GITR+CD25+Foxp3+), leading to development of autoimmune diseases (20). CD25+ T and CD25− lymphocytes inhibit the development of autoimmunity, which could also be evoked by FOXP3 expression, which, in turn, increases Treg and M2 macrophage infiltration (immunosuppression), tipping the balance in favor of the tumor cells. Polymorphisms in the Foxp3 locus affect Foxp3 expression and can influence T cell function (22). The increase in NOTCH3 also plays a role in decreasing the TMB, the GEP gene expression profile scores, and the TCD8+ activated lymphocytic infiltration. This mechanism is correlated with adenosine 2A receptor (ADORA2A) and CD276 (B7-H3) expression (23), both of which possess potential therapeutic effects (24, 25). Adenosine, which is generated in the tumor microenvironment (TME), inhibits the anti-tumor function of various immune cells, such as cytotoxic T cells and natural killer (NK) cells. Moreover, ADORA2A is implicated in the upregulation of inhibitory cytokines, such as transforming growth factor-beta (TGF-β) and inhibitory receptors, such as PD-1 itself. Interactions with FOXP3 stimulate the transformation of CD4+ T-cells into Treg cells, thus inhibiting the immune response (26).

Furthermore, T-cell activation is markedly sensitive to the depletion of glutamine and glucose, and the exogenous uptake of serine and alanine (27). Effect or T cells are consequently sensitive to the oxidative stress in the TME, which can induce the exhausted phenotype (27), which may be implicated in response and toxicity.
### TABLE 1 | Management of the most frequent severe irAEs (14) and biomarkers that may predict them.

| irAEs, all grades (≥3) (14) | Common management (grade ≥3) (14) | Special management considerations (14) | Biomarker: immune cells († except indicated) | Biomarker: cytokines († except indicated) | Other potential biomarkers |
|-----------------------------|----------------------------------|--------------------------------------|------------------------------------------|------------------------------------------|----------------------------|
| **Colitis** (<19, 13–64, 29) 38 days | Consider patient admission | Infliximab or vedolizumab | ↑CD4TH17 | IL-17 (31, 42) | Microbiome (21, 79) |
| | | ↓Tregs (41, 42) | ↓ IL-6 (31) | | |
| | | ↑CD177 and CEACAM1 genes (46) | IL-8 (31, 42) | | |
| | | | | | |
| **Dermatitis** Incidence of all dermatological irAEs: (17–37, 37–70, 48) 25 days | Steroids 1–2 mg/kg/day until grade 1, followed by a tapered dose for 4–6 weeks* | Topical emollients, corticosteroids, oral antihistamines | Consider phototherapy | ↓Circulating B cells | IL-10 (19) |
| | | | | ↑CD21⁺ B cells/plasmablasts (44) | | |
| | | | | | | |
| **Arthritis** (6–12, 5, 11) 3 months | Consider indefinite suspension of the drug * | Long-term administration of TNF inhibitor or consider tocilizumab (61) | ↓CD8 effectors (12) | IL-6 | | |
| | | | | | | |
| **Pneumonitis** (<1, 2, 7, 10) 3 months | | Infliximab or mycophenolate mofetil IV/IVIG or cyclophosphamide | ↑CD4 TH2 (12) | - | | |
| | | | | | | |
| **Thyroid disorders** Hypothyroidism (6, 4, 13), Hyperthyroidism (3, 2, 8) 14–73 days | | Hold the drug until symptoms resolve to baseline with appropriate therapy | Consider IV levothyroxine for myxoedema, steroids and supportive care | ↑CD4 TH17 (12) | - | |
| | | | | | | |

*Except thyroid disorders.

(†% PD-L1, CTLA-4, or a combination of the 2): Percentage of incidence of these irAEs according to the administered drug(s) (41).

irAEs, immune-related adverse events; PD-L1, programmed cell death ligand 1; CTLA-4, cytotoxic T-lymphocyte antigen 4; NLR, neutrophil to lymphocyte ratio.
However, T cells are not the only protagonists involved in the development of irAEs. The possible role of cytokines and other immune cells involved in the maintenance of self-tolerance, and consequently, irAE development, such as the previously mentioned NK cells, B cells, and autoantibodies, which are products of the humoral immune system, should not be forgotten.

First, cytokines such as the IL-12 family (IL-12, IL-23, IL-27, and IL-35) may be related to both tumor immunity and autoimmunity, necessitating examination of their modulation in irAEs (28). The other cytokines related to immune inhibition include IL-10, IL-4, IL-6, and IL-13 (1), and TGF-β, which is correlated with FoxP3 expression and T-reg infiltration and immunesuppression in some models (29).

Second, given that autoantibodies are associated with the development of some autoimmune diseases, such as Hashimoto’s thyroiditis and rheumatoid arthritis, autoantibodies can be considered as a potential cause of irAEs (30). However, not all antibodies play a role in the pathogenesis of irAEs.

Therefore, the development of irAEs could be related to the following mechanisms: surge in T cell activity against antigens that are present in tumors and healthy tissue, elevation in the levels of pre-existing antibodies or inflammatory cytokines, or enhancement of complement-mediated inflammation due to direct binding of anti-CTLA4 antibodies with CTLA4 expressed on normal tissue (6). These interactions could cause cellular toxicity via antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity (9).

The molecular basis of irAEs differs depending on the individual drug (31). Usually, anti PD-1-toxicity is mediated by auto antibodies that already exist in patients and are stimulated after the initiation of ICIs (32). Therefore, irAEs, such as thyroid disorders or vitiligo, are more frequent with anti-PD-1/PD-L1 drugs. Hence, we may infer that patients with a history of spontaneous autoimmune diseases would experience irAEs with greater frequency and (possibly) greater severity, which may or may not be related to the underlying autoimmune disease. The findings of studies and case reports in this regard were controversial (33–36). The reported frequency of disease flares was higher with anti PD-1/PD-L1 drugs (62 vs. 36%), while that of de novo irAEs was higher with ipilimumab (42 vs. 26%), which could be related to the previous observation on autoantibodies (37). However, although irAEs and flares are frequent among patients with autoimmune diseases (especially those with rheumatoid arthritis), their toxicities are usually manageable even without cessation of ICI therapy (38). Further evidence and guidelines are required in the future to fully understand the mechanisms underlying irAEs and autoimmunity, and advise clinicians on the safe prescription of ICIs in this context.

We must reiterate that some irAEs appear more frequently when ICIs are used for the treatment of specific tumors, albeit not in all patients. For example, the incidence of vitiligo is higher in patients with melanoma (39). Since ICIs increase the anti-tumor response via melanocytes, it is not surprising that the occurrence of vitiligo may be associated with an increased anti-tumor response (6, 40).

Colitis is another example highlighting how the development of different irAEs depends on the culprit drug. If the irAE is induced by anti-PD-L1, CD8+ T lymphocyte infiltration is observed in the intestinal mucosa, whereas irAEs caused by anti-CTLA4 are characterized by the predominance of CD4+ T cells and elevation in TNF-α levels (11). Lower levels of TNF-α in the intestinal mucosa are related to better sensitivity to corticosteroids (11).

BIOMARKERS FOR SEVERE TOXICITY

We sought biomarkers to predict irAE occurrence before their induction, in order to facilitate early treatment to avoid severe (grade 3) and life-threatening (grade 4) toxicity. The more promising ones are mentioned in this section, although none of these have been validated yet, and larger prospective studies focusing on this aspect are vital.

The first potential biomarker is related to enhanced T-cell activity against antigens present in tumor and healthy tissue; specific TCR sequences predispose cancer patients to organ-specific toxicities. For example, a lower proportion of CD8+ effector cells is associated with arthritis, while a higher proportion of CD4 TH2 cells and CD4 TH17 cells at baseline is related to pneumonitis and thyroiditis, respectively (12). It is logical to infer that a reduction in the proportion of Tregs could be related to higher toxicity, but limited data is available on its predictive ability for colitis (41, 42). Thus, the future direction for tumor immunotherapy lies in enhancing the function of tumor-specific T cells rather than that of other T-cell subtypes (43).

Furthermore, circulating B cells may be useful for predicting irAEs. Patients with melanoma treated with ICIs who experienced a 30% or greater reduction in the baseline levels of total circulating B cells, and increase in CD21lo B cells or plasma blasts, were significantly more likely to develop high-grade IRAEs than those without B cell changes (44). Interestingly, PD1 expression was higher in CD21lo B cells (45). Further studies are needed to validate these observations.

Additionally, the infiltration of digestive neutrophils into the colon during treatment is associated with digestive toxicity with anti-CTLA-4, in addition to the increased expression of the CD177 and CEACAM1 genes, which are markers of neutrophil activation (46).

First, the following useful biomarkers should be mentioned, which are simple and inexpensive to detect the neutrophil to lymphocyte ratio, which is elevated in patients who develop grade 3 and 4 pneumonitis and colitis after anti-PD-1; the absolute eosinophil count, which increases before the onset of >grade 2 endocrine disorders; and the absolute lymphocyte count (>2,000/mL). These parameters are related to irAEs, albeit without any specificity (41, 46), and can be easily altered with the incidence of other conditions such as infectious diseases, which may alter prognostication.

Second, humoral biomarkers should also be considered, since elevated levels of pre-existing antibodies or inflammatory cytokines act as triggers for the development of irAEs; IL-6, IL-17, and sCD163 are significantly associated with irAEs in cancer.
patients treated with ICIs (7, 47). CD4 TH-17 cells secreting IL-17, IL-6, and IL-8 appear in patients who develop grade > 3 colitis (with anti CTLA-4) (42, 46). The elevated levels of IL-6 and IL-10 are also linked with dermatological irAEs (19), while lower levels of IL-6 are reportedly associated with colitis (31).

Although the higher levels of autoantibodies have been linked to the irAE development, the relationship between autoantibodies and the pathogenesis of toxicities is unclear. Enhanced T-cell activation may be the most plausible trigger for irAEs, while the humoral immune system may play a supporting role. These phenomena can be measured using protein microarrays, akin to those for autoimmune diseases (48). However, anti-thyroid peroxidase (49) is the only antibody that can be employed in routine in daily clinical practice to predict irAEs. Furthermore, recent studies have found no association between baseline autoantibodies and irAE severity (30). These findings have precluded their use for the prediction of severe toxicity, and consequently, prophylactic treatment.

Finally, a few studies have posited gene signatures as a potential predictive measure for irAE incidence and severity, at least for immune-related colitis (50). A strategy that combined pharmacovigilance data with omics data identified 2 additional potential biomarkers associated with the use of PD-1/PD-L1 agents, viz. lymphocyte cytotoxic protein 1, which is involved in T-cell activation, and adenosine diphosphate dependent glucokinase, which mediates the metabolic shift during T-cell activation (51). Nevertheless, these findings were derived from a small sample, and further investigations are needed to validate these biomarkers.

The microbiome, as well as body mass index (BMI) and body composition, are the two intriguing potential biomarkers under investigation.

Fecal microbiome transplantation (FMT) has emerged as a treatment for immune-related colitis. A study showed reconstitution of the gut microbiota and elevation in Treg cells within the colonic mucosa with FMT (52). The baseline gut microbiota enriched with Faecalibacterium and other Firmicutes were found to be associated with the clinical response and CTLA-4-induced enterocolitis (42). The 2 studies reported that a low abundance of Bacteroidetes was associated with colitis. Nevertheless, to date, the studies that analyzed this issue have included a small patient population. A larger prospective studies exploring other toxicities besides colitis are needed and some of which are already underway (53).

Furthermore, recent studies show that variations in the gut microbiome have the potential to enhance the therapeutic response and reduce the irAEs associated with ICIs in multiple cancers (54, 55). The gut potential function of intestinal microbes as an immunomodulator (by increasing the anti-tumor effect and potentially reduce irAEs) is so considerable that some ongoing trials are investigating the possibility of combining them with anti PD-1/PD-L1 and anti-CTLA-4 drugs (21). The relationship of certain bacteria with vitamin B and poly-amine transport to the gastrointestinal tract may be the mechanism underlying the increased efficacy of immunotherapy in the background of the predominance of certain bacteria (56). The differences in the microbiome may apparently be responsible for toxicity or response, depending on the drug. Bacteroides fragilis, Burkholderia cepacia and the Faecalibacterium genus are associated with better response and lower incidence of colitis with anti-CTLA-4, while Bifidobacterium breve and longum, Akkermansia muciniphila, and Faecalibacterium prausnitzii are related with better outcomes with anti-PD-1/PD-L1 (56). The microbiome and its modifications may be responsible for the negative impact of some antibiotics on survival outcomes in patients receiving ICIs (57).

Another important biomarker that may be related to worse outcomes with anti-PD-1 treatment is sarcopenia. Several possible explanations exist, such as the implication of TGF-β and IL-6 and the development of chronic inflammation that results in cancer immune evasion through T cell exhaustion (58). Sarcopenia is related not only to poorer survival outcomes, but also to a higher incidence of irAEs (58). Besides, obesity has been linked with poorer outcomes with classic chemotherapy, but is apparently associated with improved outcomes in patients treated with ICIs (obesity paradox) (59). This association was especially marked when BMI and irAEs were considered in combination, meaning that the observed therapeutic benefit is further enhanced in the event of irAEs in the overweight population (60). Further studies are needed to analyse the cytokines that could be involved, as obesity is related to inflammation and metabolism, and its relationship with the hallmarks of cancer and immunotherapy requires investigation.

As mentioned above, the studies have that link potential biomarkers with irAEs are limited by their small sample size, and the unpredictable onset and frequency of these adverse events poses a challenge for the design of larger (much needed) prospective trials.

**TOXICITY ITSELF AS A BIOMARKER**

Several studies have reported a positive association between the incidence of irAEs and the survival outcomes (6, 61, 62), while others have found no such association (63). A systematic review and meta-analysis has shown that grade ≥3 toxicities were correlated with a better overall response rate, but poor overall survival (64), while another has linked irAEs with better survival and response (7).

It is possible that certain immune-related adverse events possess a more direct relationship with anti-tumor efficacy than others (6), e.g., vitiligo in patients with melanoma. Thus, the irAEs could act as biomarkers themselves; however, since the intensity of irAEs cannot be modulated at present, nor can their severity be predicted before onset, irAEs cannot be used as biomarkers of response. Doing so would jeopardize the patient by blindly exposing them to life-threatening adverse effects, owing to the lack of effective treatments that do not compromise the anti-tumor effect.

Furthermore, a few attempts were made at administering preventive treatment for the irAEs, which have been unsuccessful (65). However, it is debatable whether this could be attributed to the lack of efficacious preventive treatment or the utilization of a suboptimal biomarker.
**DISCUSSION AND FUTURE DIRECTIONS**

This review assessed several potential biomarkers for severe toxicity evoked by ICIs; however, it could not conclusively identify a definite predictive biomarker for the timing of onset and occurrence of irAEs. Unfortunately, these data do not provide sufficient evidence to design a trial that can provide early treatment modalities for irAEs. Besides, considering the potential relationship between irAEs and tumor response, attempts to stop the onset of irAEs before they effect the modifications in the immune system needed to achieve longer survival may deprive patients of the potential long-term and ulterior benefits.

The future of oncological medicine lies in immunemodulation, and in line with this approach, other options should be explored for the treatment of irAEs that do not involve the use of corticosteroids, owing to their ambiguous effect on the anti-tumor activity of the immune system, if they are not administered at the optimal time, and substantial toxicity for patients (osteoporosis, infections, hypertension, hyperglycaemia, etc.) (66, 67).

Moreover, any discussion on the discovery of immunemodulators should include not only new combination drugs, but also physical activity (PA), vitamin D, and metabolism.

First, by virtue of reducing hypoxia and normalizing the tumor vasculature (68), PA can modify the TME and significantly reduce tumor aggressiveness (69). Moreover, PA induces transformations in the AKT and mTOR pathways, muscular IL-6, and mitochondrial function, which consequently inhibit tumor cell proliferation (68). Furthermore, PA stimulates NK cells by preparing the TME for their arrival, increasing the expression of NKG2D and NKp46 receptors (70). PA can increase the cytotoxic activity of T cells and macrophages, thus lowering the risk of metastasis (69). These modifications are also observed in patients who respond better to ICIs (71–73). Hence, it seems feasible that PA could act as a potential coadjuvant to immunotherapy, as already observed in preclinical models (74).

The potential of vitamin D as an immune modulator has also garnered interest. Vitamin D seem to benefit patients with autoimmune diseases; considering that irAEs share some characteristics with them, it is reasonable to assume that vitamin D may be useful for treating or even preventing their development (75, 76). Furthermore, vitamin D may play a role in the expression of PD-L1, owing to its vast immunemodulation potential. Moreover, as patients with cancer usually have vitamin D deficiency, regular testing, and examining its relationship with the development of irAEs could be an interesting direction for research. In fact, some ongoing studies have already focused on this aspect (ClinicalTrials.gov Identifier: NCT04615988).

Furthermore, the epigenetic role of metabolism on the immune system cannot be ignored (27). Exhausted T lymphocytes inhibit the AKT and mTOR pathways, stimulating fatty acid oxidation and increasing reactive oxygen species levels, and consequently, modifications in the exhausted T lymphocytes (77). However, active T lymphocytes mainly derive energy from glycolysis even in the absence of oxygen, which is inhibited by PD-L1, at least in chronic infections, but could also be relevant for neoplasms (77). The mitochondria play a fundamental role in this mechanism, and their potential involvement in the treatment for chronic infection and tumor control is being studied. Finally, the methylation pattern for exhausted T lymphocytes has been described, which seems to confer resistance to immunotherapy (78), making this mechanism a possible focus for future investigations.

In conclusion, it is clear that future research in the fields of immunotherapy and cancer is going to take a complex route, and an independent biomarker that can predict response, toxicity, or resistance to immunotherapy is not feasible. However, the results from studies on the new immune modulators may eliminate the need for high-dose corticosteroids. Their effects on the immunemodulatory network, which are complex and sometimes contradictory, have an immense impact on toxicity, which cannot be allowed in this era of high precision medicine. We should guide our efforts to attempt to modulate the immune response to achieve better survival outcomes even without the development of irAEs.

**AUTHOR CONTRIBUTIONS**

AC-G wrote the manuscript and ML approved the final version. All authors contributed equally to the bibliographic research for this work. All authors contributed to the article and approved the submitted version.

**FUNDING**

The research grant from the University Francisco de Vitoria to AC-G covered the expenses incurred for the publication of this article.

**ACKNOWLEDGMENTS**

We are grateful to Sarah Porteus for her helpful comments on an earlier version of the manuscript.

**REFERENCES**

1. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity*. (2013) 39:1–10. doi: 10.1016/j.immuni.2013.07.012

2. Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, et al. Characterization of immune combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. *J Immunother Cancer*. (2019) 7:1–16. doi: 10.1186/s40425-019-0518-z

3. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. (2017) 28:v119–42. doi: 10.1093/annonc/mdx223

4. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events (CTCAE).v.5.0 [Sc7]. *Cancer Ther Eval Progr*. (2017) 4–155.
5. Zheng X, Wei H. Organ-specific immune-related adverse events for PD-1 antibodies in lung cancer treatment. *Front. Oncol.* (2021) 11:1–9. doi: 10.3389/fonc.2021.628243

6. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med.* (2018) 378:158–68. doi: 10.1056/NEJMra1703341

7. Zhao Z, Wang X, Qu J, Zuo W, Tang Y, Zhu H, et al. Immune-related adverse events associated with outcomes in patients with NSCLC treated with Anti-PD-1 inhibitors: a systematic review and meta-analysis. *Front. Oncol.* (2021) 11:1–12. doi: 10.3389/fonc.2021.708195

8. Ricciuti BA, Genova C, De Giglio A, Brambilla M, Bassanelli M, Dal Bello MG, et al. MA1006 impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab. *J Thorac Oncol.* (2018) 13:S390–1. doi: 10.1016/j.jtho.2018.08.399

9. Dougan M, Pietropaolo M. Time to dissect the autoimmune etiology of cancer antibody immunotherapy. *J Clin Invest.* (2020) 130:51–61. doi: 10.1172/JCI113194

10. Marthey L, Mateus C, Mussini C, Nachury M, Nancye S, Grange F, et al. Cancer immunotherapy with Anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. *J Clin Colitis.* (2016) 10:395–401. doi: 10.1093/ecco-jcc/jvy227

11. Coutzac C, Adam J, Soulaurue E, Collins M, Racine A, Mussini C, et al. Colon immune-related adverse events: Anti-CTLA-4 and Anti-PD-1 blockade induce distinct immunopathological entities. *J Clin Colitis.* (2017) 11:1238–46. doi: 10.1093/ecco-jcc/jjx081

12. Mar A, Strazza M. Bridging the gap: connecting the mechanisms of immune-related adverse events and autoimmunity through PD-1. *Front Cell Dev Biol.* (2022) 9:1–13. doi: 10.3389/fcell.2021.790386

13. Tang SQ, Tang LL, Mao YP Li WE, Chen L, Zhang Y, et al. The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients. *Cancer Res Treat.* (2021) 53:339–54. doi: 10.4134/crt.2020.790

14. Thompson, John A. Schneider, Bryan J. Brahmer, Julie. *Annals of Oncology.* (2021) 11:1–16. doi: 10.3389/fonc.2020.585311

15. Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Alba T, et al. Profiling preexisting antibodies in patients treated with Anti-PD1 therapy for advanced non–small cell lung cancer. *JAMA Oncol.* (2019) 11:1238–46. doi: 10.1001/jamaoncol.2018.5860

16. Dickson LE, Ellermann M, Connor S. Baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. *J Immunother Cancer.* (2022) 10:000408. doi: 10.1001/jnic.2022.00008

17. Homs ES, Verheijden RJ. Suikerbuijk KPM, Han D. Biomarkers of checkpoint inhibitor induced immune-related adverse events—a comprehensive review. *Front. Oncol.* (2021) 11:1–16. doi: 10.3389/fonc.2020.585311

18. Okiyama N, Tanaka R. Immune-related adverse events in various organs. *Front. Oncol.* (2021) 11:1–12. doi: 10.3389/fonc.2021.708195

19. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, et al. Adenosine A2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. *Cancer Discov.* (2020) 10:40–53. doi: 10.1158/2159-8290.CD-19-0980

20. Liu S, Liang J, Liu Z, Zhang C, Wang Y, Watson AH, et al. The Role of CD276 in Cancers. *Front. Oncol.* (2021) 11:1–11. doi: 10.3389/fonc.2021.654684

21. Ferrandino F, Grazioli P, Bellavia D, Campese AF, Screpanti I, Felli MP. Notch induces an inflammatory bowel disease. *Trends Immunol.* (2022) 42:293–311. doi: 10.1016/j.it.2021.02.006

22. Battle E, Massague J. Transforming growth factor-β signaling in immunity and cancer. *Immunity.* (2019) 50:924–40. doi: 10.1016/j.immuni.2019.03.024

23. Hoang N, Postow M, Zhu C, Janatt-Khad D, Li Q-Z, Vitone G, et al. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. *J Immunother Cancer.* (2022) 10:000408. doi: 10.1001/jnic.2022.00008

24. Ikram EM, Allam AA, Meawed TE, Abd El-Wahab SM, Ramadan M, et al. Immune checkpoint LAG3 and its ligand FGL1 in cancer. *Front. Immunol.* (2022) 13:785091. doi: 10.3389/fimmu.2021.785091
44. Liudahl SM, Coussens LM. B cells as biomarkers: predicting immune checkpoint therapy adverse events. J Clin Invest. (2018) 128:577–9. doi: 10.1172/JCI99036

45. Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, et al. Early b cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. (2018) 128:713–20. doi: 10.1172/JCI96798

46. Manson G, Norwood J, Marabelle A, Kohrt H, Hout R. Biomarkers associated with checkpoint inhibitors. Ann Oncol. (2016) 27:1199–206. doi: 10.1093/annonc/mdw181

47. Lim SY, Lee JH Gide TN, Menzies AM, Guminski A, Carlino MS, Gide TN, et al. Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFNα in melanoma. Transl Oncol. (2021) 14:101014. doi: 10.1016/j.transo.2021.101014

48. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. (2017) 35:785–92. doi: 10.1200/JCO.2015.66.1389

49. Hussenai S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – a systematic review and meta-analysis. Cancer Treat Rev. (2019) 69:102134. doi: 10.1016/j.ctrv.2019.102134

50. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. (2012) 30:2691–7. doi: 10.1200/JCO.2012.41.6759

51. Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. (2020) 11:1–7. doi: 10.1038/s41467-020-18742-9

52. Wang, Y, Wiesnoksi DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. (2018) 24:1804–8. doi: 10.1038/s41591-018-0228-9

53. Thompson NA, Stewart GD, Welsh SJ, Doherty GL, Robinson MJ, Neville BA, et al. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. BMC Cancer. (2022) 22:1–11. doi: 10.1186/s12885-021-01915-x

54. Oh B, Boyle F, Pavlakis N, Clarke S, Eade T, Hruby G, et al. The gut microbiome and cancer immunotherapy: Can we use the gut microbiome as a predictive biomarker for clinical response in cancer immunotherapy? Cancers. (2021) 13:4824. doi: 10.3390/cancers13194824

55. Shui L, Yang X, Li J, Yi C, Sun Q, Zhu H. Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy. Front Immunol. (2019) 10:2989. doi: 10.3389/fimmu.2019.02989

56. Miller PL, Carson TL. Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review. Gut Pathog. (2020) 22:1–10. doi: 10.1186/s13099-020-00381-6

57. Mielgo-Rubio X, Chara I, Soteló-Lemaza M, Lopez Castro R, Rubio-Martinez J, Velastegui A, et al. MA1001 antibiotic use and PD-1 inhibitors: shorter survival in lung cancer. Especially when given intravenously type of infection also matters. J Thorac Oncol. (2018) 13:5839. doi: 10.1016/j.jto.2018.08.039

58. Shiriyama T, Nagatomo I, Menzies AM, Zhang L, Bailur JK, et al. Impact of sarcopenia in patients with advanced non–small cell lung cancer treated with PD-1 inhibitors: a preliminary retrospective study. Sci Rep. (2019) 9:2447. doi: 10.1038/s41598-019-39120-6

59. Mochiyo Y, Seif F, Mochiyo N, Aghamajidi A, Mohsenzadegan M, Torang H-A. Efficacy of immunotherapy in obese patients with cancer. Immunopharmacol Immunotoxicol. (2022) 14:1–13. doi: 10.1080/08923937.2022.2061989

60. Rogado J, Romero-Laorden N, Sanchez-Torres JM, Ramos-Levi AM, Pacheco-Barcia V, Ballesteros AI, et al. Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies. Oncotarget. (2020) 9:1751548. doi: 10.20142/02X.20175148

61. Becerra MVS, Martínez-Cabañes R, Gonzalez-Lopez A, Zhan-Zhou E, Sotelo V, Esteban M, et al. 204P Immune-related adverse events (IrAEs) as a predictor of response to immunotherapy in patients with lung cancer. J Thorac Oncol. (2021) 16:S808–9. doi: 10.1016/S1556-0864(21)02046-3

62. Khunger A, Sarikonda G, Tsau J, Wang L, Alfonso Z, Gao J, et al. Biomarkers associated with checkpoint inhibitors. J Thorac Oncol. (2018) 128:971–5. doi: 10.1172/JCI96798

63. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. (2017) 35:785–92. doi: 10.1200/JCO.2015.66.1389
estimating the onset, severity, and subsequent prognosis of immune related adverse events. Sci Rep. (2021) 11:1–11. doi: 10.1038/s41598-020-79 397-6

81. Kostine M, Finckh A, Bingham CO, Visser K, Leiße J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. (2021) 80:36–48. doi: 10.1136/annrheumdis-2020-217139

Conflict of Interest: AC-G declares that despite the fact that the grant that covered the expenses of this article was provided by the University Francisco de Vitoria, the research course where she applied for the grant was financed by Takeda. ML was employed by Centro Estudios Biosanitarios.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Cardeña-Gutiérrez and López Barahona. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.